prikaz prve stranice dokumenta SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism
  Download
PDF 665.61 KB
Scientific paper - Original scientific paper
SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism
Biomedicines, 10 (2022), 12; 3237. https://doi.org/10.3390/biomedicines10123237
Nedić Erjavec, Gordana; Grubor, Mirko; Živković, Maja; Božina, Nada; Šagud, Marina; Nikolac Perković, Matea; Mihaljević-Peleš, Alma; Pivac, Nela; Švob Štrac, Dubravka

Cite this document

Nedić Erjavec, G., Grubor, M., Živković, M., Božina, N., Šagud, M., Nikolac Perković, M. ... Švob Štrac, D. (2022). SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism. Biomedicines, 10. (12). doi: 10.3390/biomedicines10123237

Nedić Erjavec, Gordana, et al. "SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism." Biomedicines, vol. 10, no. 12, 2022. https://doi.org/10.3390/biomedicines10123237

Nedić Erjavec, Gordana, Mirko Grubor, Maja Živković, Nada Božina, Marina Šagud, Matea Nikolac Perković, Alma Mihaljević Peleš, Nela Pivac and Dubravka Švob Štrac. "SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism." Biomedicines 10, no. 12 (2022). https://doi.org/10.3390/biomedicines10123237

Nedić Erjavec, G., et al. (2022) 'SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism', Biomedicines, 10(12). doi: 10.3390/biomedicines10123237

Nedić Erjavec G, Grubor M, Živković M, Božina N, Šagud M, Nikolac Perković M, and sur.. SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism. Biomedicines [Internet]. 2022 December 13 [cited 2024 April 10];10(12). doi: 10.3390/biomedicines10123237

G. Nedić Erjavec, et al., "SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism", Biomedicines, vol. 10, no. 12, December 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:746134. [Accessed: 10 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism
AuthorGordana Nedić Erjavec
AuthorMirko Grubor
AuthorMaja Živković
AuthorNada Božina
AuthorMarina Šagud
AuthorMatea Nikolac Perković
AuthorAlma Mihaljević-Peleš
AuthorNela Pivac
AuthorDubravka Švob Štrac
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pharmacology)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Psychiatry and Psychological Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Psychiatry
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Pharmacology
Abstract (english)
Antipsychotic-induced parkinsonism (AIP) is the most common type of extrapyramidal side effect (EPS), caused by the blockage of dopamine receptors. Since dopamine availability might influence the AIP risk, the dopamine transporter (DAT) and serotonin receptors (5-HTRs), which modulate the dopamine release, may be also involved in the AIP development. As some of the individual differences in the susceptibility to AIP might be due to the genetic background, this study aimed to examine the associations of SLC6A3, HTR2C and HTR6 gene polymorphisms with AIP in haloperidol-treated schizophrenia patients. The Extrapyramidal Symptom Rating Scale (ESRS) was used to evaluate AIP as a separate entity. Genotyping was performed using a PCR, following the extraction of blood DNA. The results revealed significant associations between HTR6 rs1805054 polymorphism and haloperidol-induced tremor and rigidity. Additionally, the findings indicated a combined effect of HTR6 T and SLC6A3 9R alleles on AIP, with their combination associated with significantly lower scores of ESRS subscale II for parkinsonism, ESRS-based tremor or hyperkinesia and ESRS subscales VI and VIII. These genetic predictors of AIP could be helpful in better understanding its pathophysiology, recognizing the individuals at risk of developing AIP and offering personalized therapeutic strategies for the patients suffering from this EPS.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBiomedicines
Numberingvol. 10, no. 12, 3237
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines10123237
URN:NBNurn:nbn:hr:105:746134
Publication2022-12-13
Document URLhttps://www.mdpi.com/2227-9059/10/12/3237
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-04-26 12:15:09